Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial
Journal article
Jenkin D. et al, (2023), The Lancet Infectious Diseases, 23, 956 - 964
Evaluation of T cell responses to naturally processed variant SARS-CoV-2 spike antigens in individuals following infection or vaccination.
Journal article
Yin Z. et al, (2023), Cell reports, 42
Higher antigen occupancy of high avidity CSP serum antibodies associates with protection against human malaria
Journal article
Li K. et al, (2023), Biophysical journal, 122, 144a - 145a
A tool for evaluating heterogeneity in avidity of polyclonal antibodies.
Journal article
Li K. et al, (2023), Frontiers in immunology, 14
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial.
Journal article
Datoo MS. et al, (2022), The Lancet. Infectious diseases, 22, 1728 - 1736
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial
Journal article
Madhavan M. et al, (2022), eBioMedicine, 85, 104298 - 104298
Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial
Journal article
Jenkin D. et al, (2022), The Lancet Microbe, 3, e663 - e671
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
Journal article
Ogbe A. et al, (2022), JCI Insight, 7
CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination
Journal article
Sharpe HR. et al, (2022), JCI Insight, 7
Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial
Journal article
Bosaeed M. et al, (2022), The Lancet Microbe, 3, e11 - e20
A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial
Journal article
Folegatti PM. et al, (2021), Nature Communications, 12
Characterisation of the T-cell response to Ebola virus glycoprotein amongst survivors of the 2013–16 West Africa epidemic
Journal article
Tipton TRW. et al, (2021), Nature Communications, 12
AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein–specific TH1 response with a diverse TCR repertoire
Journal article
Swanson PA. et al, (2021), Science Translational Medicine, 13
Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial.
Journal article
Bosaeed M. et al, (2021), The Lancet. Microbe
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
Journal article
Feng S. et al, (2021), Nature Medicine, 27, 2032 - 2040
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
Journal article
Flaxman A. et al, (2021), The Lancet, 398, 981 - 990
Efficacy and Safety of a Modified Vaccinia Ankara-NP+M1 Vaccine Combined with QIV in People Aged 65 and Older: A Randomised Controlled Clinical Trial (INVICTUS)
Journal article
Butler C. et al, (2021), Vaccines, 9, 851 - 851
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial
Journal article
Frater J. et al, (2021), The Lancet HIV, 8, e474 - e485
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Journal article
Barrett JR. et al, (2021), Nature Medicine, 27, 1113 - 1113
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
Journal article
Ewer KJ. et al, (2021), Nature Medicine, 27, 1116 - 1116